US start-up Samay has reported clinical data showing that its Sylvee wearable device can accurately diagnose chronic obstructive pulmonary disease (COPD), and even predict potentially fatal exacerbations before they happen.

美国初创公司Samay报告了临床数据，显示其Sylvee可穿戴设备可以准确诊断慢性阻塞性肺病（COPD），甚至可以在发生之前预测潜在的致命性恶化。

The San Francisco Bay area company – formerly known as Respira Labs – said the artificial intelligence-assisted device was able to detect ‘air trapping,’ an early predictor of COPD exacerbations, with 83% accuracy compared to hospital-based pulmonary function tests (PFTs) based on in-person spirometry and plethysmography tests or CT scans..

旧金山湾区公司-以前称为Respira Labs-表示，人工智能辅助设备能够检测“空气陷阱”，这是COPD恶化的早期预测因子，与基于医院的肺功能测试（PFT）相比，准确率为83%）基于面对面肺量计和体积描记测试或CT扫描。。

It also diagnosed COPD with 90% accuracy and identified statistically significant associations in medication efficacy during pre- and post-bronchodilation PFTs, according to Samay, which said it plans to publish its findings once additional patient data is available from the study.

Samay表示，它还诊断出COPD的准确率为90%，并在支气管扩张前后PFT中发现药物疗效的统计学显着相关性，Samay表示，一旦该研究获得额外的患者数据，它计划公布其研究结果。

Sylvee is worn on the chest around the clock and uses tiny speakers and microphones to project sound into the lungs and listen for returning signals – called acoustic resonance – that could indicate serious lung diseases. The prototype device is paired with the Sylvee mobile app and a research portal..

Sylvee全天候戴在胸部，用微型扬声器和麦克风将声音投射到肺部，听到返回的信号（称为声音共振），这些信号可能表明严重的肺部疾病。原型设备与Sylvee移动应用程序和研究门户网站配对。。

Along with trapped air, the device also monitors lung function over time – using measures such as lung volume, capacity, and rates of flow – to provide a comprehensive overview of a patient’s condition.

除了滞留的空气外，该设备还可以监测肺功能-使用肺容量，容量和流速等措施-全面了解患者的病情。

Dr Maria Artunduaga

Maria Artunduaga博士

Maria Artunduaga, Samay’s founder and CEO, said the company’s vision is “to enable clinicians to intervene early and monitor frequent exacerbators closely, decreasing hospitalisations.”

Samay的创始人兼首席执行官Maria Artunduaga表示，该公司的愿景是“使临床医生能够及早干预并密切监测频繁发生的恶化，减少住院治疗。”

COPD is the third leading cause of death worldwide, and affects an estimated 12.5 million people in the US, leading to 150,000 deaths, according to 2020 data, although those numbers are likely underestimated as COPD is still underdiagnosed and underreported.

根据2020年的数据，COPD是全球第三大死亡原因，影响美国约1250万人，导致15万人死亡，尽管这些数字可能被低估，因为COPD仍未被诊断和报告不足。

The disease is also one of the most expensive chronic conditions, generating healthcare costs of over $30 billion per year in the US. Much of that cost is driven by exacerbations, the sudden and life-threatening deterioration in lung function experienced by COPD patients.

该疾病也是最昂贵的慢性病之一，在美国每年产生超过300亿美元的医疗费用。其中大部分费用是由COPD患者经历的肺功能突然恶化和危及生命的恶化所驱动的。

Dr Artunduaga named the Sylvee device after her grandmother Sylvia, who passed away following complications when her COPD exacerbation initially went undetected.

Artunduaga博士在她的祖母Sylvia之后命名了Sylvee设备，她的祖母Sylvia在COPD恶化最初未被发现时因并发症去世。

“Exacerbations or flare-ups of chronic lung conditions cause a major burden on patients, families, and global healthcare systems,” according to Ruth Tal-Singer, former chief executive and chief scientific officer of the COPD Foundation, who sits on Samay’s scientific advisory board.

根据Samay科学顾问委员会前任COPD基金会首席执行官兼首席科学官Ruth Tal Singer的说法，“慢性肺部疾病的恶化或爆发给患者，家属和全球医疗系统带来沉重负担”。

“They are often diagnosed and treated late, as worsening of respiratory symptoms may be felt well after the biological changes occur,” she said. “An effort-independent, simple, non-invasive approach to remotely monitoring, detecting and reporting early changes in air trapping offers a fantastic opportunity to start treatment and prevent severe outcomes such as hospitalisation.”.

她说：“他们经常被诊断和治疗得很晚，因为在发生生物学变化后可能会感觉到呼吸道症状恶化。”。“采用独立于努力，简单，无创的方法远程监测，检测和报告空气滞留的早期变化，为开始治疗和预防住院等严重后果提供了绝佳的机会。”。